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Abstract
Background: To undertake a systematic review of the available data for oral and intravenous topotecan in adults
with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first line regimen is not considered
appropriate.
Methods: We searched six databases from 1980 up to March 2009 for relevant trials regardless of language or
publication status. Relevant studies included any randomised trial of any chemotherapeutic treatment against any
comparator in this licensed indication. Where possible we used apposite quantitative methods. Where meta-
analysis was considered unsuitable for some or all of the data, we employed a narrative synthesis method. For
indirect comparisons we used the method of Bucher et al., where available data allowed it, otherwise we used
narrative descriptions.
Results: Seven unique studies met the inclusion criteria, four of which could be used in our analyses. These
included one study comparing oral topotecan plus best supportive care (BSC) to BSC alone, one study comparing
intravenous topotecan to cyclophosphamide, adriamycin and vincristine (CAV), and two studies comparing oral
topotecan with intravenous topotecan. All four studies appear to be well conducted and with low risk of bias.
Oral topotecan plus BSC has advantages over BSC alone in terms of survival (hazard ratio = 0.61; 95% CI, 0.43 to
0.87) and quality of life (EQ-5 D difference: 0.15; 95% CI, 0.05 to 0.25). Intravenous topotecan was at least as effec-
tive as CAV in the treatment of patients with recurrent small-cell lung cancer and resulted in improved quality-of-
life with respect to several symptoms.
CAV was associated with significantly less grade 4 thrombocytopenia compared with IV topotecan (risk ratio = 5.83;
95% CI, 2.35 to 14.42). Survival (hazard ratio = 0.98; 95% CI, 0.77 to 1.25) and response (pooled risk ratio = 1.04;
95% CI, 0.58 to 1.85) data were similar for the oral and IV topotecan groups. Symptom control was also very similar
between the trials and between the oral and IV groups. Toxicity data showed a significant difference in favour of
oral topotecan for neutropenia (pooled risk ratio = 0.65; 95% CI, 0.47 to 0.89).
Indirect evidence showed that oral topotecan was at least as good as or better than CAV on all outcomes (survival,
response rates, toxicities, and symptoms) that allowed indirect comparisons, with the only exception being grade
four thrombocytopenia which occurred less often on CAV treatment.
Conclusions: Concerning topotecan both the oral and intravenous options have similar efficacy, and patient
preference may be a decisive factor if the choice would be between the two formulations. The best trial evidence
for decision making, because it was tested versus best supportive care, exists for oral topotecan. Indirectly, because
we have two head-to-head comparisons of oral versus intravenous topotecan, and one comparison of intravenous
topotecan versus CAV in similar patients as in the trial against best supportive care, one might infer that IV
topotecan and CAV could also be superior to best supportive care, and that oral topotecan has similar effects to
CAV with possibly better symptom control. From the evidence discussed above, it is evident that oral topotecan
has similar efficacy to IV topotecan (direct comparison) and CAV (indirect comparison). There is no further evidence
base of direct or possible indirect comparisons for other comparators than CAV of either oral or IV topotecan.
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Small cell lung cancer (SCLC) is a type of lung cancer
which grows rapidly and spreads quickly to distant sites.
Common symptoms of SCLC include weight loss,
malaise, bone pain, breathlessness and haemoptysis.
SCLC is frequently associated with distinct paraneoplas-
tic syndromes which are not due to direct invasion of
adjacent tissues by the cancer or its metastases, for
example, neurological or endocrine syndromes.
Lung cancer accounts for around 33,000 deaths per
year in England and Wales[1,2]. It is estimated that
SCLC constitutes about 10% of the total cases represent-
ing about 3,300 new cases per year. Of these, around 24%
are classed as limited stage at diagnosis (tumour confined
to one side of the chest or to the neck lymph nodes),
while the remainder have extensive stage disease (defined
a st h ep r e s e n c eo fo b v i o u sm e tastatic disease). The pro-
portion of lung cancer cases of small cell type has been
steadily falling over the years and reasons for this are
unclear, but it has been attributed to changing smoking
habits and a reduction in the tar content of cigarettes.
The prognosis of SCLC is poor; the life expectancy of
those with untreated SCLC is about 3.5 months for lim-
ited disease and 6 weeks for extensive disease[3]. Prog-
nosis has been linked to performance status and extent
of disease, among other factors[4,5].
Current management usually consists of combination
chemotherapy regimens. Median survival with such
cytotoxic treatment is approximately 14 to 18 months
for limited disease and 9 to 12 months for extensive dis-
ease. Radiotherapy may be given concurrently with che-
motherapy or as part of palliative care. Surgery is only
suitable for a small minority of patients with no evi-
dence of local spread or metastasis.
The NICE lung cancer clinical guideline (No. 24)
advises that all patients with newly diagnosed SCLC
should be offered a platinum-based chemotherapy, and
multi-drug regimes[6]. Patients with limited-stage SCLC
should be offered thoracic irradiation concurrently with
the first or second cycle of chemotherapy, or following
completion of chemotherapy if there has been at least a
good partial response within the thorax. For patients
with extensive disease, thoracic irradiation should be
considered following chemotherapy if there has been a
complete response at distant sites and at least a good
partial response within the thorax. Second-line che-
motherapy should be offered to patients at relapse only
if their disease responded to first-line chemotherapy.
Topotecan (Hycamtin, GlaxoSmithKline) acts by inhi-
biting topoisomerase I, an enzyme that is required for
DNA replication, leading to cell death. It can be admi-
nistered either orally or intravenously. Topotecan is
indicated as monotherapy for patients with relapsed
small cell lung cancer [SCLC] for whom re-treatment
with the first-line regimen is not considered appropriate.
Topotecan hard capsules gained a positive opinion
from the Committee for Human Medicinal Products
(CHMP) on 24 January 2008 “as monotherapy for the
treatment of adult patients with relapsed small cell lung
cancer (SCLC) for whom re-treatment with the first line
regimen is not considered appropriate.” [7].
The definition of relapsed SCLC needs careful consid-
eration and distinction should be made between patients
who relapse within 3 months of first line therapy (often
called refractory disease) in whom second line che-
motherapy or best supportive care (BSC) are the treat-
ment options, and patients who relapse more than
3 months after therapy (relapsed disease, “sensitive” dis-
ease) in whom re-treatment with first line therapy is the
standard approach. Standard first line chemotherapy has
historically been cyclophosphamide, doxorubicin (adria-
mycin) and vincristine (CAV) though increasingly plati-
num/etoposide (PE) is the preferred regimen. However,
it is also possible other regimens were used as first-line
therapy and/or are used as second line therapy in
relapsed patients. For example, a fairly recent health
technology assessment report from AHRQ in the United
States focused on radiotherapy, but also presented
results from nine randomised trials which had made 9
different comparisons for second- or subsequent-line
treatment of SCLC[8]. Two randomised trials had
directly compared chemotherapy with best supportive
care for recurrent SCLC[9,10].
Based on the AHRQ report and clinical experience
from Europe it seems that there may be a broad set of
possible comparators in clinical practice. It would be
useful to include an analysis of randomised trials per-
formed in the appropriate patient groups which have
used any comparator and consider them for indirect
comparisons with topotecan and, if the data allow, pos-
sibly as a network meta-analysis[11]. The basic principle
of such an approach is that if a randomised trial of A
versus B, and another randomised trial of B versus C
exist with the same patient characteristics, an indirect
comparison of A versus C is possible.
Our aim was to undertake a comprehensive systematic
review of topotecan and all relevant comparator thera-
pies for the treatment of relapsed SCLC.
Methods
Inclusion criteria
We included any randomised trial of any chemothera-
peutic treatment against any comparator in patients
with SCLC who have relapsed after first line therapy in
whom re-treatment with thef i r s tl i n er e g i m e ni sn o t
considered appropriate.
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We attempted to identify all relevant trials regardless of
language or publication status (published, unpublished,
in press, and in progress). The search strategies (key-
words) were developed specifically for each database (see
Additional files 1, 2 and 3). We searched the following
databases from 1980 up to September 2008: MEDLINE,
EMBASE, CDSR, CENTRAL, DARE, and HTA: Update
searches were performed in March 2009.
Furthermore, references in retrieved articles and sys-
tematic reviews were checked, and the internet was
searched via Google for relevant studies. Also the web-
sites of licensing agencies and HTA agencies were
checked. Identified references were downloaded in
Reference Manager software for further assessment and
handling.
Methods of trial selection, quality assessment and data
extraction
Trial selection
Two reviewers independently inspected the abstract of
each reference identified by the search and determine
the potential relevance of each article. For potentially
relevant articles, or in cases of disagreement, the full
article was obtained, independently inspected, and inclu-
sion criteria applied. Any disagreements were resolved
through discussion.
Assessment of methodological quality
We used the Cochrane Collaboration quality assessment
checklist[12]. Quality assessment was carried out inde-
pendently by two reviewers. Any disagreements were
resolved by consensus. The results of the quality assess-
ment were used for descriptive purposes to provide an
evaluation of the overall quality of the included studies
and to provide a transparent method of recommenda-
tion for design of any future studies. In addition, we
planned if enough data were available from the included
studies, to include each of the quality components as
explanatory variables in a meta-regression analysis to
investigate the association of each of these components
with study results as a way of explaining possible het-
erogeneity. However, this was not possible as we only
included 4 studies (See Additional file 4 and the Results
section). Based on the findings of the quality assessment,
recommendations are made for the conduct of future
studies.
Data collection
For each study, data were extracted independently by
two reviewers. Any disagreements were resolved by
consensus.
The following main information was extracted for stu-
dies: author, year, country, aim of the study, duration of
follow up, description of the participants included in the
study, predefined inclusion and/or exclusion criteria,
and number of participants recruited/included in the
study, details and characteristics of the interventions
and control treatments (dosage, length of treatment),
number of patients with outcome data per group, rea-
sons for withdrawals and dropouts per group.
Dichotomous data were extracted as the number of
individuals with the outcome of interest and the total
numbers of individuals in the intervention and control
group. Continuous data were extracted as the mean and
standard deviation (SD) for the intervention and control
group. Survival data were extracted as the hazard ratio
and its standard error. Where necessary, we used the
formula [upper limit of the 95% CI minus lower limit of
the 95% CI] divided by 3.92 to estimate the standard
error from the 95% CI, as recommended in the
Cochrane Handbook[12].
F i n a l l yw ee x t r a c t e dt h eo v e r a l lc o n c l u s i o no ft h e
study, provided a summary statement of the overall
quality of each study, and any additional comments on
the study.
Data synthesis
Where meta-analysis was considered unsuitable for
some or all of the data, we employed a narrative synth-
esis method. This involved the use of narrative text and
tables to summarise data in order to allow the reader to
consider outcomes in the light of differences in study
designs and potential sources of bias for each of the stu-
dies being reviewed. This also involved organizing the
studies by (as appropriate) intervention, population, or
outcomes assessed, summarizing the results of the stu-
dies, summarizing the range and size of the associations
these studies report, and describing the most important
characteristics of the included studies. A detailed com-
mentary on the major methodological problems or
biases that affected the studies is also included, together
with a description of how this in our judgement has
affected the individual study results.
However, where possible we used the following quan-
titative methods:
Dichotomous data were analysed by calculating the
relative risk (RR) for each trial using the DerSimonian
and Laird’s method and the corresponding 95% confi-
dence intervals. Continuous data were analysed using
the (weighted) mean difference between groups and the
corresponding 95% confidence interval. Survival data
were analysed by using the hazard ratio (HR) and its
standard error (estimated as described above from the
95% CI where not given in the original paper).
We anticipated that systematic differences between
studies (heterogeneity) would be likely. Therefore, the
random-effects model was used for the calculation of
relative risks or weighted mean differences. Heterogene-
ity was initially assessed by measuring the degree of
inconsistency in the studies’ results (I
2). This measure
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2) describes the percentage of total variation across
studies that is due to heterogeneity rather than the play
of chance. The value of I
2 lies between 0% and 100%,
and a simplified categorization of heterogeneity could be
low, moderate, and high to I
2 values of 25%, 50%, and
75%.
In the event of important heterogeneity we intended
to formally investigate it using meta regression; however,
this was not possible because results of only two studies
could be pooled.
Statistical analyses were performed using RevMan
(version 5) software.
For indirect comparisons we used the method of
Bucher et al. (1997)[13], where available data allowed it,
otherwise we used narrative descriptions. Bucher’s
method was implemented using RevMan by performing
subgroup analyses, the different subgroups being defined
by the different comparisons being made. For the parti-
cular case of two subgroups (two comparisons; three
interventions) the difference between the subgroups can
be estimated, and the statistical significance determined,
using Bucher’s method. In this review, one subgroup
would be the ‘oral topotecan versus IV topotecan’ trials,
and the other subgroup the ‘CAV versus IV topotecan’
trial. The difference between the summary effects in the
two subgroups provided an estimate of the desired com-
parison, ‘oral topotecan versus CAV’.T h et e s tw a sp e r -
formed using the test for differences between subgroups,
as implemented in RevMan version 5.
Sub-group analysis Where sufficient data were available
we planned to present subgroup analyses to investigate
whether the efficacy differs according to:
￿ age group
￿ gender
￿ performance status
￿ prior therapy
￿ extent of disease
￿ presence of any liver metastases
￿ patients for whom an IV chemotherapy is unsuitable
￿ patients with serious pre-existing cardiovascular or
neurological conditions, for whom treatment with an
anthracycline-based regimen would not be clinically
appropriate
￿ time to relapse/progression
Results
Our searches of the databases for topotecan trials
yielded 2,467 titles and abstracts; of these we ordered
and assessed 133 full papers for possible inclusion, and
from these 133 papers, 7 unique studies met the inclu-
sion criteria (figure 1).
Of the 133 full papers which we assessed for possible
indirect comparisons, 66% were excluded because they
reported on patients who did not previously receive
chemotherapy, 14% were not randomised trials, 9% did
not have any usable comparator (e.g. studies randomis-
ing to different dosages of the same intervention), and
6% treated patients who were in complete remission.
Thus, we identified seven studies (5%) for our ana-
lyses. These included one study comparing oral topote-
can plus best supportive care to best supportive care
alone (O’Brien 2006[9]), one study comparing intrave-
nous topotecan to CAV (von Pawel 1999[14]), two stu-
dies comparing oral topotecan with intravenous
topotecan (von Pawel 2001[15], Eckardt 2007[16]), one
study comparing etoposide/cisplatinum with bis-chloro-
ethynylnitrosourea/thiotepa/vincristine/cyclophospha-
mide (O’Bryan et al 1990[17]), one study comparing
CCNU/cyclophosphamide/etoposide with CAV (Gervais
et al. 2007[18]) and one study comparing topotecan
with amrubicin (Inoue et al. 2008[19]).
The study by O’Brien et al addresses the question:
“What is the evidence that chemotherapy can have ben-
eficial effects in these patients?” This question is best
answered by a randomised trial of chemotherapy plus
best supportive care versus best supportive care alone.
The three studies by Von Pawel 1999 & 2001 and
Eckardt 2007 address the question “What is the evi-
dence for the comparative effects of different che-
motherapeutic treatments in these patients?” This
question is best answered by a randomised trial with
head-to-head comparisons. Patients in these three trials
had recurrence at least 60 days, 3 months and 90 days
after the end of first-line chemotherapy, respectively.
For these patients re-treatment with first line therapy is
the standard approach. The licence indication for topo-
tecan states that it is for patients “for whom re-treatment
with the first line regimen is not considered appropriate”.
The fact that these patients were selected for topotecan
trials led us to assume they were unsuitable for
Medline 559 
Embase 1735 
Cochrane Library, search terms: “small cell lung 
cancer not "non small" and (relapsed or Recurrent or 
advanced or recurrence)”
Central 173 trials 
Total 2467 records 
Assessed 133 full papers 
Included 7 studies 
Excluded 2,334 
Excluded 126 
Figure 1 Search strategy.
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fulfilled our inclusion criteria.
The study by Gervais et al. 2007 only provided a meth-
ods description of the trial and no results are reported;
the study by O’Bryan et al. 1990 provided no comparator
that is common to any of the other studies; while the
study by Inoue et al. 2008 uses a lower dose (1.0 mg/m
2)
than usual for intravenous topotecan. Therefore we did
not include these three studies for our analyses.
This left the network of available comparisons as
presented in figure 2.
The totality of this evidence addresses the main ques-
tions about oral topotecan for second-line treatment in
relapsed patients with resistant or sensitive disease.
Based on our searches, it appears that only for oral
topotecan randomised trials addressing both questions
exist. For CAV and for intravenous topotecan we did
not find a randomised study assessing their efficacy ver-
sus best supportive care in these patients. Actually, for
second-line treatment in these patients we found no
other randomised trials of CAV.
The quality of these studies is presented in Additional
file 4. Given that blinding of investigators (physicians)
and patients would be very difficult with these regiments,
t h e r ei sl i k e l yt ob es o m er i s ko fb i a sr e s u l t i n gf r o mt h i s .
However, in general all 4 studies appear to be well con-
ducted and with low risk of bias.
Direct comparisons
The main characteristics of the included studies are pre-
sented in table 1.
The most important effectiveness outcomes are sum-
marised in table 2 and table 3 shows adverse events.
None of the comparisons concerning the effectiveness
outcomes showed a statistically significant advantage for
either BSC or CAV. Several outcomes showed statisti-
cally significant advantages for topotecan, these are pre-
sented in bold.
Oral topotecan versus best supportive care
Table 2 shows that for important effectiveness outcomes
oral topotecan plus best supportive care has advantages
over best supportive care alone. O’Brien et al. conclude
that “chemotherapy with oral topotecan is associated
with prolongation of survival and quality of life benefit
in patients with relapsed small-cell lung cancer.
Intravenous topotecan versus CAV
The study by von Pawel et al 1999 concludes that (intrave-
nous) topotecan was at least as effective as CAV in the
Oral topotecan 
Intravenous 
topotecan 
CAV 
Best supportive 
care 
etoposide 
/cisplatinum
bis-chloro-
ethynylnitrosourea 
/ thiotepa / 
vincristine / 
cyclophosphamide
Figure 2 Network of Available Comparisons.
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and resulted in improved control of several symptoms.
Oral topotecan versus intravenous topotecan
Two studies assessed oral versus intravenous topotecan,
and these have included similar patients and used the
same interventions. A number of the outcomes allow
meta-analysis, and others can be compared narratively.
Combined overall response rates show no differences
between oral and intravenous topotecan, although the I
2
statistic shows moderate heterogeneity (figure 3). The
cause is not immediately apparent, but von Pawel 2001
has a limited number of event rates and a wide 95%
confidence interval.
Survival data were similar in both trials and similar for
the oral and IV topotecan groups. In the Eckardt 2007
trial, median survival time was 33.0 weeks (95% CI, 29.1
to 42.4 weeks) in the oral group and 35.0 weeks (95%
CI, 31.0 to 37.4 weeks) in the IV group, with data cen-
sored for 13.7% and 10.6% of patients in the respective
groups. Cox proportional hazards regression showed no
difference between the two groups (hazard ratio = 0.98;
95% CI, 0.77 to 1.25). At 1 year, the survival rate was
Table 1 Main characteristics of included trials
O’Brien 2006 Von Pawel 1999 Von Pawel 2001 Eckardt 2007
Comparison Oral topotecan (2.3 mg/m
2/d
on days 1-5 every 21 days)
vs BSC
IV topotecan (1.5 to 2 mg/
m
2/d (as 30-minute infusion)
on days 1-5 every 21 days)
vs CAV (cyclophosphamide
1,000 mg/m
2 (max 2,000
mg), doxorubicin 45 mg/m
2
(max 100 mg), and
vincristine 2 mg,
administered on day 1 of
each course)
Oral (2.3 mg/m
2/d) vs IV
topotecan (1.5 mg/m
2/d
(as 30-minute infusion) on
days 1-5 every 21 days)
Oral (2.3 mg/m
2/d) vs IV
topotecan (1.5 mg/m
2/d (as
30-minute infusion) on days
1-5 every 3 weeks)
Design Multinational, multicentre,
open-label, phase III RCT
Multinational, multicentrel
open-label RCT
Multinational, multicentre,
open-label, phase II RCT
Multinational, multicentre,
open-label, phase III RCT
N 141 211 106 304
Inclusion
criteria
Documented relapse of limited
or extensive SCLC at least 45
days after the cessation of first-
line chemotherapy. Not
considered suitable for further
intravenous chemotherapy.
Received one prior
chemotherapy regimen only.
Documented partial or
complete response to first-line
therapy.
Patients with documented
progressive, limited or
extensive SCLC that had
recurred at least 60 days after
the end of first-line
chemotherapy
Patients with limited or
extensive SCLC that had
recurred at least 3 months
after the end of first-line
chemotherapy. Received one
prior chemotherapy regimen
only.
Patients with limited or
extensive SCLC and
documented complete or
partial response to first-line
therapy with disease
recurrence after ≥90 days.
Received one prior
chemotherapy regimen only
Mean age
(range)
59.2 (37-79) years Not reported 59.0 (35-79) years 62.2 (35-82) years
% extensive
disease
65% 84% 72% 68%
Performance
status (% 0/1/2)
10/60/29% 18/61/21% 26/52/22% 27/60/13%
Previous
chemotherapy
Not reported Platinum/etoposide: 48% CAV:
1%
Not reported cisplatinum or carboplatinum +
etoposide;
Both platinum/etoposide +
CAV: 14% Cyclophosphamide/
doxorubicin/etoposide : 17%
vincristine + cisplatinum or
carboplatinum + etoposide;
Vincristine/platinum/etoposide:
5% Other regimens: 15%
cyclophosphamide
+epirubicine + cisplatinum or
carboplatinum + etoposide
Previous
surgery
27% 21% Not reported Not reported
Previous
radiotherapy
51% 59% Not reported Not reported
Previous
immunotherapy
3% 1% Not reported Not reported
Liver
metastases
24% 40% 31% 29%
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treatment with IV topotecan; the 2-year survival rates
were 12% for oral topotecan and 7% for IV topotecan.
In the von Pawel 2001 trial, median survival was 32
weeks in the oral group and 25 weeks in the IV group.
The risk ratio (oral:IV) for survival was 0.84 (95% CI,
0.53 to 1.32), and accounted for prognostic factors
(response and duration of response to previous therapy,
sex, presence of renal impairment at baseline, perfor-
mance status, presence of baseline liver metastases,
extent of disease, previous radiotherapy, and maximum
tumor diameter) it was 0.90 (95% CI, 0.55 to 1.47).
Symptom control was also very similar between the
trials and between the oral and IV groups.
Toxicity data show a few differences, with neutropenia
(pooled risk ratio = 0.65 (95% CI, 0.47 to 0.89) and leu-
copenia (pooled risk ratio = 0.80 (95% CI, 0.56 to 1.14)
showing a tendency in favour of oral topotecan, which
for neutropenia is significant in both studies; and with
tendencies towards better effects for IV topotecan for
thrombocytopenia (pooled risk ratio = 1.42 (95% CI,
0.99 to 2.03) and anaemia (pooled risk ratio = 1.66 (95%
CI, 0.61 to 4.52).
Indirect comparisons
In addition to these direct comparisons, it was possible
to perform indirect comparisons for oral topotecan ver-
sus CAV (via intravenous topotecan) and intravenous
topotecan versus best supportive care (via oral topote-
can). The study characteristics (table 1) show that nor-
mal assumptions for making indirect comparisons
between oral topotecan and CAV are fulfilled: all trials
included similar patients, the IV topotecan regimens
were similar, follow up was similar and a number of the
same outcomes are available.
Survival time
In the Eckardt 2007 trial, median survival time was
33.0 weeks (95% CI, 29.1 to 42.4 weeks) in the oral
Table 2 Main outcomes
O’Brien 2006 Von Pawel 1999 Von Pawel 2001 Eckardt 2007
Oral topotecan vs BSC IV topotecan vs CAV Oral vs IV
topotecan
Oral vs IV topotecan
Overall
survival
(median)
25.9 (18.3 to 31.6) weeks vs 13.9
(11.1 to 18.6) weeks
25 (0.4 to 90.7) weeks vs
24.7 (1.3 to 101.3) weeks
32.3 (0.4-69.1)
weeks vs 25.1
(0.6-65.1) weeks
33.0 (29.1 to 42.4) weeks vs 35.0 (31.0 to 37.4)
weeks
Overall
survival
[hazard
ratio]
0.61 (0.43 to 0.87) 1.04 (0.78 to 1.40)† Risk ratio 0.90
(0.55 to 1.47)
0.98 (0.77 to 1.25)
Progression free survival
Time to
progression
16.3 (12.9 to 20.0) weeks* 13.3 (0.4 to 55.1) weeks vs
12.3 (0.1 to 75.3) weeks
15 weeks vs 13
weeks
Response
rate [risk
ratio]
1.33 (0.79 to 2.25)$ 1.56 (0.69 to 3.50)
$
0.84 (0.53 to 1.31)$
Response
rate
7%* 24.3% (16.2 to 32.4)
vs18.3% (10.8 to 25.7);
difference 6.0% (-6 to 18)
23% vs 15%
difference 8.3%
(-6.6% to 23.1%)
18.3% (12.2 to 24.4) vs 21.9% (15.3 to 28.5%)
difference - 3.6% (-12.6% to 5.5%)
Complete
response
0% vs 1%
Response
duration
14.4 (9.4 to 50.1) weeks vs
15.3 (8.6 to 69.9) weeks
18 weeks vs 14
weeks
18.3 weeks vs 25.4 weeks
Stable
disease
44%* 19.6% vs 11.5%; OR 1.87
(0.87 to 4.03)$
Quality of
Life
Difference in rate of change EQ-
5 D 0.15 (0.05 to 0.25) in favour
of topotecan
FACT-L total score (change from baseline)
-5.07 (-7.49 to -2.65) vs -5.67 (-8.05 to 3.28);
difference 0.59 (-2.38 to 3.57)#
Effects in bold show advantage for topotecan; effects in italics show advantage for best supportive care or CAV (none were found); numbers between brackets
are 95% confidence intervals
*only provided for topotecan group
vs = versus
$ = own calculation from 2 by 2 data
# = data supplied by GlaxoSmithKline
† = data from EMEA: EPAR - Hycamtin-H-123-II-34; see:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000123/WC500051543.pdf
BSC: best supportive care
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in the IV group. In the Von Pawel 2001 trial, median
survival was 32 weeks in the oral group and 25 weeks
in the IV group. In the Von Pawel 1999 trial, median
survival was 25 weeks for the IV topotecan group,
and 24.7 weeks for CAV. Survival is therefore very
similar in all trials, allowing the conclusion that survi-
val for oral topotecan is not worse than survival on
CAV.
The calculated hazard ratio between oral topotecan
and CAV (using Bucher’s method) is HR = 1.02 (95%
CI: 0.70, 1.49) and between IV topotecan and BSC:
HR = 0.62 (95% CI: 0.41, 0.95).
Overall response rates
O’Brien et al. 2007 only reported response rates for
patients treated with topotecan. Therefore, an indirect
comparison of IV topotecan versus BSC for response
can not be performed.
The figure for overall response rates below (figure 4)
shows us that the confidence intervals almost comple-
tely overlap, demonstrating that similar response rates
are found between oral topotecan and CAV. The p-
value for subgroup differences (and thus for the indirect
comparison) is 0.45. The calculated risk ratio between
oral topotecan and CAV (using Bucher’sm e t h o d )i sR R
= 1.29 (95% CI: 0.67, 2.50), indicating a non-significant
advantage for oral topotecan.
Toxicity
O’Brien et al. 2007 only reported toxicity data for
patients treated with topotecan. Therefore, an indirect
comparison of IV topotecan versus BSC for toxicity can
not be performed.
Table 3 Improvement in symptom control
O’Brien 2006 Von Pawel 1999 Von Pawel 2001 Eckardt 2007
Improvement in: Oral topotecan vs
BSC
IV topotecan vs
CAV
Oral vs IV
topotecan
Oral vs IV topotecan#
Shortness of
breath
OR 2.18 (1.09 to
4.38)
27.9% vs 6.6% P =
0.002
13.8% vs 27.3% P =
0.20$
0.009 (-0.21 to 0.23) vs 0.08 (-0.29 to 0.14) difference 0.08
(-0.22 to 0.39)†
Cough OR 1.35 (0.68 to
2.66)
24.6% vs 14.8% P =
0.16
16.1% vs 22.2% P =
0.53$
0.14 (-0.07 to 0.36) vs 0.27 (0.07 to 0.46) difference -0.13
(-0.41 to 0.16)†
Chest pain OR 2.07 (1.00 to
4.28)
25.0% vs 17.1% P =
0.371
42.1% vs 31.8% P =
0.50$
-0.18 (-0.40 to 0.03) vs 0.06 (-0.11 to 0.23) difference -0.24
(-0.52 to 0.03)†
Coughing up
blood
OR 1.95 (0.46 to
8.27)
26.7% vs 33.3% P =
0.706
33.3% vs 40.0% P =
0.84$
Loss of appetite OR 1.02 (0.57 to
1.84)
32.1% vs 15.8% P =
0.042
18.5% vs 31.0% P =
0.28$
Interference with
sleep
OR 2.16 (1.15 to
4.06)
33.3% vs 18.9% P =
0.085
32.0% vs 26.6% P =
0.85$
Hoarseness OR 1.35 (0.63 to
2.87)
32.5% vs 13.2% P =
0.043
35.7% vs 37.5% P =
0.91$
Fatigue OR 2.29 (1.25 to
4.19)
22.9% vs 9.2%
P = 0.032
21.2% vs 16.7% P =
0.63$
Interference with
daily activities
OR 1.70 (0.95 to
3.03)
26.9% vs 11.1% P =
0.023
25.8% vs 22.2% P =
0.73$
Nausea -0.42 (-0.60 to -0.24) vs -0.40 (-0.60 to -0.21) difference -0.02
(-0.28 to 0.24)†
Pain -0.08 (-0.28 to 0.12) vs -0.40 (-0.60 to -0.21) difference 0.09
(-0.22 to 0.40)†
Effects in bold show advantage for topotecan; effects in italics show advantage for best supportive care or CAV (none were found); numbers between brackets
are 95% confidence intervals; BSC best supportive care; OR = odds ratio; vs versus; $ = own calculation from 2 by 2 data; † = data supplied by GlaxoSmithKline; #
a positive change indicates improvement
Study or Subgroup
Eckardt 2007
Von Pawel 2001
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.08; Chi² = 1.72, df = 1 (P = 0.19); I² = 42%
Test for overall effect: Z = 0.13 (P = 0.90)
Events
28
12
40
Total
153
52
205
Events
33
8
41
Total
151
54
205
Weight
65.3%
34.7%
100.0%
M-H, Random, 95% CI
0.84 [0.53, 1.31]
1.56 [0.69, 3.50]
1.04 [0.58, 1.85]
Oral topotecan IV topotecan Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favours IV topotecan Favours oral topotecan
Figure 3 Overall response rates.
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are reported. As can be seen from the direct compari-
sons, IV topotecan was associated with significantly
more grade 4 thrombocytopenia compared with CAV;
and IV topotecan was associated with significantly
more grade 4 neutropenia compared with oral topote-
can. The indirect comparisons, using Bucher’sm e t h o d ,
showed that CAV was associated with significantly
more grade 4 neutropenia compared with oral topote-
can; while oral topotecan was associated with signifi-
cantly more grade 4 thrombocytopenia compared with
CAV.
Symptom control
Unfortunately, data about symptoms were not presented
in similar ways to allow indirect comparisons. However,
the study comparing IV topotecan with CAV reported
improved control of several symptoms, whereas the stu-
dies of oral versus IV topotecan reported similar effects
on symptoms. This allows at least speculation that oral
topotecan would also have better symptom control than
CAV.
Conclusions from indirect comparisons
Overall, oral topotecan was at least as good as or better
than CAV on all outcomes (survival, response rates,
toxicities, and symptoms) that allowed indirect compari-
sons, with the only exception being grade four thrombo-
cytopenia which occurred less often on CAV treatment.
Discussion
Topotecan is indicated as monotherapy for patients with
relapsed small cell lung cancer for whom re-treatment
with the first-line regimen is not considered appropriate.
This indication has an important nuance that deserves
further qualification: when is re-treatment with first line
regimen not considered appropriate?
The included studies operationalised this issue as fol-
lows: the O’Brien study accepted patients with recur-
rence less than 60 days after the end of first-line
chemotherapy, but 70% of patients had recurrence more
than 60 days after the end of first-line chemotherapy.
Von Pawel’s two studies included patients with recur-
rence at least 60 days after the end of first-line che-
motherapy, whereas the Eckardt study included patients
with disease recurrence after ≥90 days. Data from these
trials, but also from various phase II studies confirm
that patients have a better prognosis with a longer inter-
val before recurrence, but the O’Brien trial showed that
even patients with poorer prognosis due to shorter
interval before recurrence still have survival benefit
from oral topotecan (median survival 23.3 weeks; 95%
CI 10.7 to 30.9) compared with best supportive care
(13.2 weeks; 95% CI 7.0 to 21.0). The NICE lung cancer
clinical guideline, which states that second-line che-
motherapy should be offered to patients at relapse only
if their disease responded to first-line chemotherapy,
Figure 4 Overall response rates*. * The test for subgroup differences is only possible using the fixed effect model in RevMan. The difference
in relative risks between figure 3 and 4 is due to the fact that the random effects model gives relatively more weight to smaller trials.
Table 4 Risk ratios for toxicity results
IV topotecan vs CAV
1 IV vs Oral topotecan
2 Oral topotecan vs CAV
3
Grade 4 neutropenia 0.98 (0.82 to 1.17) 1.47 (1.22 to 1.78) 0.67 (0.51 to 0.87)
Grade 4 thrombocytopenia 5.83 (2.35, 14.42) 0.70 (0.49 to 1.01) 8.41 (3.17 to 22.35)
Grade 4 anaemia 1.46 (0.25 to 8.54) 0.60 (0.22 to 1.65) 2.46 (0.33 to 18.53)
1- Direct comparison (Von Pawel 1999); 2- Direct comparison (Von Pawel 2001 & Eckardt 2007); 3- Indirect comparison (Von Pawel 1999/Von Pawel 2001 &
Eckardt 2007).
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Page 9 of 12does not quantify a time frame until recurrence, and
states that second-line treatment should be discussed on
an individual basis.
The trials show clinical disagreement about the period
between 60 and 90 days, but there seems to be general
agreement that from 90 days onwards re-treatment with
first line chemotherapy should be considered. In addi-
tion to the issue of what is the exact cut-off in days
after first-line treatment when recurrence appeared,
there are other issues that play a role. The O’Brien
study addresses this issue in some detail and gives a
number of reasons why retreatment with first-line ther-
apy might not be appropriate, including patient prefer-
ence (table 5)[9].
This concurs with the NICE guidance that second-line
treatment should be discussed on an individual basis,
and with the findings of Liu et al 1997[20].
Three out of the four included studies (O’Brien 2006,
von Pawel 1999 and von Pawel 2001) reported the pre-
sence of liver metastases as a factor that negatively influ-
enced the outcomes. Von Pawel 2001 reported that
patients with baseline liver metastases had a risk that
was 1.9 times that of patients without for time to pro-
gression. Von Pawel 1999, in a logistic regression model
evaluating the effects of baseline characteristics identi-
fied presence of baseline liver metastases and sex as
the only significant factors of response (P=.043 and
P=.008, respectively). O’Brien 2006 found a more
favourable point estimate for the effect of topotecan in
patients without liver metastases, although the confi-
dence intervals overlapped. However, data in patients
with liver metastases are very limited and none of the
authors suggested that patients with liver metastases
should be considered differently.
A recent systematic review arrived at largely similar
conclusions as our review[21]. Cheng et al 2007
reported that the evidence for the clinical benefit of sec-
ond-line chemotherapy in the treatment of patients with
relapsed SCLC is limited. The selection of patients for
treatment with second-line therapy should be dependent
on the treatment-free interval, the extent of response to
first-line therapy, residual toxicity from first-line ther-
apy, and the performance status of the patient. They go
on to conclude that there is insufficient evidence to
recommend a specific chemotherapy regimen. Neverthe-
l e s s ,i nt h eo p i n i o no ft h el u n gc a n c e rd i s e a s es i t e
group, patients who relapse three or more months after
having completed first-line chemotherapy may benefit
from re-treatment with the same regimen that induced
their initial response. This would generally mean re-
treatment with etoposide and cisplatin. Alternative regi-
mens may include CAV or carboplatin and etoposide.
Topotecan is a possible alternative for patients who
initially respond to chemotherapy and who have
response duration of 45 days or longer. Topotecan may
be administered orally or intravenously. Available evi-
dence has not yet established a superior mode of admin-
istration, and each has different benefits and toxicities.
Oral administration is associated with a higher incidence
of grade 3/4 diarrhoea, whereas IV administration may
result in a higher frequency of grade 3/4 neutropenia.
The final conclusion from Cheng et al 2007 is that there
is currently no standard second-line chemotherapy regi-
men for patients who fail to respond to or who relapse
shortly after first-line therapy. Clinical trials are needed
to determine the optimal treatment regimen.
Through our searches we found three ongoing studies.
T h ef i r s ts t u d yi sar a n d o m i z e dp h a s eI Is t u d y ,o ft o p o -
tecan versus amrubicin in patients with relapsed SCLC
following first-line chemotherapy, results of which were
presented by Jotte et al. at the World Lung Cancer Con-
gress 2009 (NCT00319969). Jotte et al. reported a
response rate of 44% for amrubicin versus 11.5% for
topotecan, with median overall survival of 9.3 versus 7.7
months in favour of amrubicin. The second study was a
randomised Phase III study of topotecan versus amrubi-
cin as second line therapy in 620 patients with SCLC
(NCT00547651). This study completed accrual in 2010
and is expected to be completed in March 2011. The
third study is a comparison of picoplatin (a platinum-
based chemotherapy) + BSC versus BSC alone in
patients with relapsed SCLC (NCT00465491). The
expected completion date is May 2009, but as far as we
know results have not yet been published.
So what are the treatment options in patients who
relapse after first-line treatment? In addition to topote-
can, best supportive care is one, and also CAV. There is
a paucity of randomised trials in this group of patients;
Table 5 Study 478: Potential reasons for not being suitable for repeat first line treatment
Reasons Relevance to study 478 population
Short time to progression 54% of patients in the trial had a treatment free interval (TFI) of ≤90 days
Residual toxicity to first line regimen 13% of patients in the best supportive care + topotecan arm and 10% in the best supportive care
arm had residual toxicity
Patient preference not to receive further
intravenous chemotherapy
O’Brien et al report that some patients in the study with sensitive SCLC refuse further intravenous
chemotherapy because of the risk of toxicity or become unsuitable for standard chemotherapy
because of co-morbidities
Riemsma et al. BMC Cancer 2010, 10:436
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CAV was the comparator in one of these topotecan stu-
dies. For CAV and for intravenous topotecan we did not
find a randomised study assessing their effects versus
best supportive care in these patients. Actually, for sec-
ond-line treatment in patients who relapsed after first-
line treatment, we found no other randomised trials of
CAV.
Concerning topotecan both the oral and intravenous
options have similar effects, and patient preference may
be a decisive factor if the choice would be between the
two formulations. The best trial evidence for decision
making, because it was tested versus best supportive
care, exists for oral topotecan. Indirectly, because we
have two head-to-head comparisons of oral versus intra-
venous topotecan, and one comparison of intravenous
topotecan versus CAV in similar patients as in the trial
against best supportive care, one might infer that IV
topotecan and CAV could also be superior to best sup-
portive care, and that oral topotecan has similar effects
as CAV with possibly better symptom control. So for
patients suitable for additional treatment, topotecan or
CAV would be superior treatment options when com-
pared with best supportive care. For patients not willing
or unable to have intravenous treatment, oral topotecan
is the only choice with evidence of efficacy from rando-
mised trials. According to the study by Liu et al 1997,
patients with incurable cancer have a clear preference
for oral chemotherapy, but are generally not willing to
sacrifice efficacy for their preference. Almost 40% of
patients did not want to make final treatment decisions
themselves. From the evidence discussed above, it is evi-
dent that oral topotecan has similar efficacy to IV topo-
tecan (direct comparison) and CAV (indirect
comparison). There is no further evidence base of direct
or possible indirect comparisons for other comparators
than CAV of either oral or IV topotecan.
Conclusion
There is high unmet medical need to offer further active
treatment in relapsed SCLC and therefore improve out-
comes in patients for whom currently available IV sec-
ond line chemotherapy is not considered an option and
therefore whose only treatment option is currently best
supporting care (BSC). Topotecan is indicated for the
treatment of patients with relapsed small cell lung can-
cer (SCLC) for whom re-treatment with the first line
regimen is not considered appropriate. When compared
with BSC alone, oral topotecan combined with BSC
extends overall survival, disease-free survival and posi-
tively improves quality-of-life across a number of symp-
toms in SCLC patients who have relapsed following first
line therapy.
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